Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain
Open Access
- 25 July 2000
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 7 (15) , 1304-1311
- https://doi.org/10.1038/sj.gt.3301221
Abstract
Recombinant adeno-associated viruses (rAAVs) can transduce several tissues, including the brain. However, in brain the duration of gene expression in different areas is variable, which has been ascribed to viral (CMV) promoter silencing in some regions over time. We have compared expression of enhanced green fluorescent protein (EGFP) in the nigrostriatal pathway of rats mediated by rAAVs containing the CMV or platelet-derived growth factor-β chain (PDGF-β) promoter. In addition, we studied the effects of the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) on transgene expression in vivo. The rAAV vectors containing the neuron-specific PDGF-β chain promoter transduced significantly more dopaminergic neurons than titer-matched vectors carrying the CMV promoter. Moreover, the WPRE further increased EGFP expression, and a rAAV vector incorporating both the PDGF-β chain promoter and the WPRE resulted in efficient EGFP expression in dopaminergic neurons and their projections in the striatum for at least 41 weeks after virus injection. Our results emphasize the importance of a strong tissue-specific promoter in achieving optimal transgene expression, not only in long-term but also in short-term studies where viral titers may be limiting. Furthermore, they suggest that incorporation of the WPRE into rAAVs, and possibly other types of vectors, is useful to enhance transgene expression in vivo.Keywords
This publication has 32 references indexed in Scilit:
- Enhanced Expression of Transgenes from Adeno-Associated Virus Vectors with the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element: Implications for Gene TherapyHuman Gene Therapy, 1999
- Induction of Immunity to Antigens Expressed by Recombinant Adeno-Associated Virus Depends on the Route of AdministrationClinical Immunology, 1999
- Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vectorNature Medicine, 1999
- Adeno-Associated Viral Vectors for Gene Transfer and Gene TherapyBiological Chemistry, 1999
- In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vectorGene Therapy, 1998
- Selective and Rapid Uptake of Adeno-Associated Virus Type 2 in BrainHuman Gene Therapy, 1998
- Neuron-Specific Transduction in the Rat Septohippocampal or Nigrostriatal Pathway by Recombinant Adeno-associated Virus VectorsExperimental Neurology, 1998
- Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson’s disease in ratsProceedings of the National Academy of Sciences, 1997
- Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectorsNature Genetics, 1997
- Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vectorBrain Research, 1996